ahf
FDA unconvinced on Novartis heart drug
March 26, 2014Research and Development, Sales and Marketing FDA, Novartis, ahf, heart, serelaxin
The prospects of Novartis’ latest heart drug being approved in the US anytime soon appear to have been scuppered by …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
